Critical Reviews in Oral Biology & Medicine, Vol 6, 147-160, Copyright © 1995 by International & American Associations for Dental Research

ARTICLES

Oral leukoplakia

J. J. Sciubba
Department of Dental Medicine, Long Island Jewish Medical Center, New Hyde Park, New York 11040, USA.

Leukoplakia has evolved as a clinico-pathologic concept over many years, with the current clinical designation being accepted worldwide. Reflective of the biology of leukoplakia is the concept of cellular atypia and epithelial dysplasia. Adding to a better understanding of leukoplakia in general has been the definition of relevant clinical subsets which, in some cases, includes etiology (snuff), while in other cases a verrucous clinical appearance will suggest a more aggressive anticipated behavior pattern. Tobacco usage, in many of its forms, remains the prime etiologic factor; however, other considerations also apply. More recently, the potential etiologic role of Candida albicans has been stressed, as well as its possible role in carcinogenesis. So-called oral hairy leukoplakia has been defined in relation to a possible Epstein-Barr viral infection, usually in the immunosuppressed patient. Other viruses, human papilloma virus in particular, have been implicated in leukoplakia, while genetic alterations involving tumor suppressor elements (p53) have also been investigated. Finally, the management of this common condition remains a variable and includes local, topical, and systemic therapies such as anti-oxidants, carotenoids, and retinoids.

This article has been cited by other articles:

				S. R. Mallery, J. C. Zwick, P. Pei, M. Tong, P. E. Larsen, B. S. Shumway, B. Lu, H. W. Fields, R. J. Mumper, and G. D. Stoner Topical Application of a Bioadhesive Black Raspberry Gel Modulates Gene Expression and Reduces Cyclooxygenase 2 Protein in Human Premalignant Oral Lesions Cancer Res., June 15, 2008; 68(12): 4945 - 4957. [Abstract] [Full Text] [PDF]

				B. S. Shumway, L. A. Kresty, P. E. Larsen, J. C. Zwick, B. Lu, H. W. Fields, R. J. Mumper, G. D. Stoner, and S. R. Mallery Effects of a Topically Applied Bioadhesive Berry Gel on Loss of Heterozygosity Indices in Premalignant Oral Lesions Clin. Cancer Res., April 15, 2008; 14(8): 2421 - 2430. [Abstract] [Full Text] [PDF]

				C. Scully and J.-V. Bagan ADVERSE DRUG REACTIONS IN THE OROFACIAL REGION Crit. Rev. Oral. Biol. Med., July 1, 2004; 15(4): 221 - 239. [Abstract] [Full Text] [PDF]

				C. M. Rudin, E. E.W. Cohen, V. A. Papadimitrakopoulou, S. Silverman Jr, W. Recant, A. K. El-Naggar, K. Stenson, S. M. Lippman, W. K. Hong, and E. E. Vokes An Attenuated Adenovirus, ONYX-015, As Mouthwash Therapy for Premalignant Oral Dysplasia J. Clin. Oncol., December 15, 2003; 21(24): 4546 - 4552. [Abstract] [Full Text] [PDF]

				I. Ganly and B. Singh Topical ONYX-015 in the Treatment of Premalignant Oral Dysplasia: Another Role for the Cold Virus? J. Clin. Oncol., December 15, 2003; 21(24): 4476 - 4478. [Full Text] [PDF]